Cargando…

Checkpoint blockade accelerates a novel switch from an NKT-driven TNFα response toward a T cell driven IFN-γ response within the tumor microenvironment

BACKGROUND: The temporal response to checkpoint blockade (CB) is incompletely understood. Here, we profiled the tumor infiltrating lymphocyte (TIL) landscape in response to combination checkpoint blockade at two distinct timepoints of solid tumor growth. METHODS: C57BL/6 mice bearing subcutaneous MC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aoyama, Shota, Nakagawa, Ryosuke, Nemoto, Satoshi, Perez-Villarroel, Patricio, Mulé, James J, Mailloux, Adam William
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Basic Tumor Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8211075/ https://www.ncbi.nlm.nih.gov/pubmed/34135102 http://dx.doi.org/10.1136/jitc-2020-002269

Ejemplares similares

Glucocorticoid activation by HSD11B1 limits T cell-driven interferon signaling and response to PD-1 blockade in melanoma
por: Martins Nascentes Melo, Luiza, et al.
Publicado: (2023)

MCT4 blockade increases the efficacy of immune checkpoint blockade
por: Babl, Nathalie, et al.
Publicado: (2023)

Optimizing therapeutic outcomes of immune checkpoint blockade by a microbial tryptophan metabolite
por: Renga, Giorgia, et al.
Publicado: (2022)

Antimetabolite pemetrexed primes a favorable tumor microenvironment for immune checkpoint blockade therapy
por: Lu, Chia-Sing, et al.
Publicado: (2020)

Downregulation of phosphoserine phosphatase potentiates tumor immune environments to enhance immune checkpoint blockade therapy
por: Peng, Zhi-Peng, et al.
Publicado: (2023)

Gallic acid induces T-helper-1-like T(reg) cells and strengthens immune checkpoint blockade efficacy
por: Deng, Biaolong, et al.
Publicado: (2022)

Deep immunophenotyping at the single-cell level identifies a combination of anti-IL-17 and checkpoint blockade as an effective treatment in a preclinical model of data-guided personalized immunotherapy
por: Nagaoka, Koji, et al.
Publicado: (2020)

Fc-null anti-PD-1 monoclonal antibodies deliver optimal checkpoint blockade in diverse immune environments
por: Moreno-Vicente, Julia, et al.
Publicado: (2022)

Ambra1 modulates the tumor immune microenvironment and response to PD-1 blockade in melanoma
por: Frias, Alex, et al.
Publicado: (2023)

Heterologous prime-boost vaccination targeting MAGE-type antigens promotes tumor T-cell infiltration and improves checkpoint blockade therapy
por: McAuliffe, James, et al.
Publicado: (2021)

Inducible Tertiary Lymphoid Structures: Promise and Challenges for Translating a New Class of Immunotherapy
por: Aoyama, Shota, et al.
Publicado: (2021)

IL-6 signaling in macrophages is required for immunotherapy-driven regression of tumors
por: Beyranvand Nejad, Elham, et al.
Publicado: (2021)

Extracellular HMGB1 blockade inhibits tumor growth through profoundly remodeling immune microenvironment and enhances checkpoint inhibitor-based immunotherapy
por: Hubert, Pascale, et al.
Publicado: (2021)

Preconditioning of the immune system modulates the response of papillary thyroid cancer to immune checkpoint inhibitors
por: Pani, Fabiana, et al.
Publicado: (2022)

TYRO3 blockade enhances anti-PD-1 therapy response by modulating expression of CCN1 in tumor microenvironment
por: Park, Miso, et al.
Publicado: (2023)

Induction of Tertiary Lymphoid Structures With Antitumor Function by a Lymph Node-Derived Stromal Cell Line
por: Zhu, Genyuan, et al.
Publicado: (2018)

Glutathione peroxidase 2 is a metabolic driver of the tumor immune microenvironment and immune checkpoint inhibitor response
por: Ahmed, Kazi Mokim, et al.
Publicado: (2022)

Impact of CD4 T cells on intratumoral CD8 T-cell exhaustion and responsiveness to PD-1 blockade therapy in mouse brain tumors
por: Khan, Saad M, et al.
Publicado: (2022)

Tumor MHC class I expression alters cancer-associated myelopoiesis driven by host NK cells
por: Neo, Shi Yong, et al.
Publicado: (2022)

Inhibition of tumor intrinsic BANF1 activates antitumor immune responses via cGAS-STING and enhances the efficacy of PD-1 blockade
por: Wang, Minglei, et al.
Publicado: (2023)

Tumor-specific T cells support chemokine-driven spatial organization of intratumoral immune microaggregates needed for long survival
por: Abdulrahman, Ziena, et al.
Publicado: (2022)

Chemoradiation triggers antitumor Th1 and tissue resident memory-polarized immune responses to improve immune checkpoint inhibitors therapy
por: Lauret Marie Joseph, Elodie, et al.
Publicado: (2021)

Activated NK cells reprogram MDSCs via NKG2D-NKG2DL and IFN-γ to modulate antitumor T-cell response after cryo-thermal therapy
por: Peng, Peng, et al.
Publicado: (2022)

Targeting SNORA38B attenuates tumorigenesis and sensitizes immune checkpoint blockade in non-small cell lung cancer by remodeling the tumor microenvironment via regulation of GAB2/AKT/mTOR signaling pathway
por: Zhuo, Yue, et al.
Publicado: (2022)

Activated but impaired IFN-γ production of mucosal-associated invariant T cells in patients with hepatocellular carcinoma
por: Huang, Wenyong, et al.
Publicado: (2021)

EMBR-32. INTEGRATED STRESS RESPONSE PLAYS A PRO-SURVIVAL ROLE IN MYC-DRIVEN MEDULLOBLASTOMA
por: Langman, Sofya, et al.
Publicado: (2021)

Blockades of effector T cell senescence and exhaustion synergistically enhance antitumor immunity and immunotherapy
por: Liu, Xia, et al.
Publicado: (2022)

The role of IFN-γ-signalling in response to immune checkpoint blockade therapy
por: Wong, Chun Wai, et al.
Publicado: (2023)

Inhibition of myeloperoxidase enhances immune checkpoint therapy for melanoma
por: Liu, Tracy W, et al.
Publicado: (2023)

Local IFNα enhances the anti-tumoral efficacy of systemic anti-PD1 to prevent tumor relapse
por: Guerin, Marion v, et al.
Publicado: (2020)

Skin immunization for effective treatment of multifocal melanoma refractory to PD1 blockade and Braf inhibitors
por: Hao, Xingxing, et al.
Publicado: (2021)

Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy
por: Halle, Briana Rose, et al.
Publicado: (2021)

Dynamical modeling of proliferative-invasive plasticity and IFNγ signaling in melanoma reveals mechanisms of PD-L1 expression heterogeneity
por: Subhadarshini, Seemadri, et al.
Publicado: (2023)

Androgen receptor blockade resistance with enzalutamide in prostate cancer results in immunosuppressive alterations in the tumor immune microenvironment
por: Xu, Pengfei, et al.
Publicado: (2023)

Maximizing cancer therapy via complementary mechanisms of immune activation: PD-1 blockade, neoantigen vaccination, and Tregs depletion
por: D'Alise, Anna Morena, et al.
Publicado: (2021)

Differential quantities of immune checkpoint-expressing CD8 T cells in soft tissue sarcoma subtypes
por: Klaver, Yarne, et al.
Publicado: (2020)

Interaction between tumor cell TNFR2 and monocyte membrane-bound TNF-α triggers tumorigenic inflammation in neuroblastoma
por: Tomolonis, Julie A, et al.
Publicado: (2023)

N-cadherin inhibitor creates a microenvironment that protect TILs from immune checkpoints and Treg cells
por: Sun, Yi, et al.
Publicado: (2021)

Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastoma
por: Simonds, Erin F, et al.
Publicado: (2021)

Therapy of lymphoma by immune checkpoint inhibitors: the role of T cells, NK cells and cytokine-induced tumor senescence
por: Ahmetlic, Fatima, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_is001asb06ads0hgdoamn95gaq